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Identification of a Role for the ARHGEF3 Gene
in Postmenopausal Osteoporosis
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Frank Dudbridge,5 and Scott G. Wilson1,3,4,*
Osteoporosis is a common and debilitating bone disease characterized by low bone mineral density (BMD), a highly heritable and poly-
genic trait. Genome-wide linkage studies have identiﬁed 3p14-p21 as a quantitative trait locus for BMD. The ARHGEF3 gene is situated
within this region and was identiﬁed as a strong positional candidate. The aim of this study was to evaluate the role of variation in
ARHGEF3 on bone density in women. Sequence variation within ARHGEF3 was analyzed with 17 single-nucleotide polymorphisms
(SNPs) in a discovery cohort of 769 female sibs. Signiﬁcant associations were found with family-based association tests between ﬁve
SNPs and various measures of age-adjusted BMD (p ¼ 0.0007–0.041) with rs7646054 showing maximal association. Analysis of the
data with QPDTPHASE suggested that the more common G allele at rs7646054 is associated with decreased age-adjusted BMD. Signif-
icant associations were also demonstrated between 3-SNP haplotypes and age-adjusted spine and femoral-neck BMD (p ¼ 0.002 and
0.003, respectively). rs7646054 was then genotyped in a replication cohort, and signiﬁcant associations with hip and spine BMD
were conﬁrmed (p¼ 0.003–0.038), as well as an associationwith fracture rate (p¼ 0.02). Again, theG allele was associatedwith a decrease
in age-adjusted BMD at each site studied. In conclusion, genetic variation in ARHGEF3 plays a role in the determination of bone density
in Caucasian women. This data implicates the RhoGTPase-RhoGEF pathway in osteoporosis.Introduction
Postmenopausal osteoporosis is a systemic bone disease
that is characterized by low bone mass and disturbed
microarchitecture of bone tissue, resulting in increased fra-
gility, and is a major risk factor for fracture.1 Peak bone
mass is attained in early adult life but declines in postmen-
opausal women as a result of a reduction in estrogen pro-
duction with effects on bone as well as intestinal and renal
calcium handling.2 However, in addition to the effects
of estrogen, calcium, and other environmental factors on
bone structure and fracture, there is a strong genetic effect
on peak bone mass, bone loss, and fracture rates in post-
menopausal women.3–6 Twin and family studies show
that 50%–90% of the variance in peak bone mass is herita-
ble.3,4,6–10 The whole-genome linkage-scanning approach
has identiﬁed at least 11 replicated quantitative trait loci
(QTLs),11–20 so that it is evident that the genetic effect
for common variation in bone mineral density (BMD) is
under polygenic control. The 3p14-p21 region of the hu-
man genome has been identiﬁed as one of the most repli-
cated QTLs for BMD in multiple studies, including our
own19 and a meta-analysis.21 The ARHGEF3 gene, which
encodes the rho guanine-nucleotide exchange factor
(GEF) 3, is situated within this region.
The ARHGEF3 gene was selected for study on the basis
of a bioinformatics analysis, including physical location
of the gene relative to maximum LOD score for the linkage
at 3p14-p21, gene function, conserved domains found in
the protein by BLASTp, and number of homologs and1262 The American Journal of Human Genetics 82, 1262–1269, Jungene family members identiﬁed by BLASTp. The product
of this gene speciﬁcally activates two members of the
RhoGTPase family: RHOA (MIM 165390),22 known to
play a role in bone,23,24 and RHOB (MIM 165370),22 with a
potential role in osteoarthritis.25,26 Interestingly, variation
in the gene FGD1 (MIM 300546), encoding another
RhoGTPase regulatory protein, has been implicated in
the Aarskog-Scott Syndrome (AAS [MIM 305400]), which
is characterized by a variety of skeletal abnormalities in-
cluding short stature, hypertelorism, and brachydactyly.27
This paper reports a study of the effect of polymor-
phisms within the ARHGEF3 gene on bone density in a
large, well-described, family-based cohort of women from
Australia and the United Kingdom with replication in an
independent cohort of postmenopausal women from the
UK.
Material and Methods
Subjects
Discovery Cohort
A total of 769 women from 335 families were recruited in Australia
and the UK. This family-based population included siblings
recruited for a study of the genetics of osteoporosis in 1998.19
The median BMD Z score for the proband at the spine, total-hip,
and femoral-neck sites was Z ¼ 1.54 (1.03), 1.00 (0.95), and
1.03 (1.05), respectively (interquartile range). Sibships within
the cohort included 264 families with two siblings, 49 with three,
17 with four, four with ﬁve, and one with seven siblings. The
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measurements were spine Z ¼ 2.2 (1.59), total-hip Z ¼ 1.5 (1.04),
and femoral-neck Z ¼ 1.6 (1.17). Exclusion criteria were applied
where possible and included the presence of bone cancer, hyper-
parathyroidism, unstable thyroid disease, long-term steroid use
(>5 mg/day for more than 6 months and presently on therapy),
chronic immobility, rheumatoid arthritis, anorexia nervosa, osteo-
malacia, amenorrhea for>6months,prematurecessationof regular
menstruation or surgical oophorectomy5 hormone-replacement
therapy (age< 40 yr), and epilepsywith use of anticonvulsantmed-
ication for > 1 yr. All subjects from the study provided written
informed consent, and the institutional ethics committees of par-
ticipating institutions approved the experimental protocols.
At a clinic visit, data including age, height, weight, medical,
gynecological, and lifestyle data were recorded and a blood sample
was collected. Dual-energy X-ray absorptiometry (DXA) BMD was
assessed (Hologic, Bedford, MA, USA) at the lumbar spine L1–L4
and the total hip, which includes an area from the femoral neck
to just below the lesser trochanter. Within this area, the femoral-
neck subregion is widely used in clinical practice for prediction
of fracture propensity and was the phenotype chosen for use in
this study. Because of the range of ages in this cohort, BMD data
were adjusted for age prior to analysis by conversion to BMD Z
scores. The correlations between the BMD Z scores obtained
from different sites were r ¼ 0.82 (total hip and femoral neck), r ¼
0.63 (total hip and spine), and r ¼ 0.52 (femoral neck and spine).
Replication Cohort
This group of subjects was recruited in 1988 to participate in a lon-
gitudinal epidemiological study of rheumatic diseases (The Ching-
ford Study). Women between the ages of 45 and 64 were recruited
from a single large general practice in Chingford, North-East Lon-
don, via a population-based method. All women within this age
range that were on a register of more than 11,000 patients were
invited to participate in the study. No exclusion criteria were ap-
plied. This cohort has similar demographics and anthropometry
to the general UK population regarding height, weight, smoking
status, and hysterectomy rates.28,29 Demographic and lifestyle-fac-
tor data were obtained from questionnaires completed in 1988.
DNA samples were obtained from 780 individuals. Bone-density
measurements were undertaken with a Hologic QDR-2000 densi-
tometer in 1998, approximately 10 yr after the subjects were ini-
tially recruited, with hip and spine DXA BMD data obtained
from 775 and 779 individuals, respectively. The correlations be-
tween the BMD measurements obtained from different sites were
r ¼ 0.89 (total hip and femoral neck), r ¼ 0.7 (total hip and spine),
and r¼ 0.67 (femoral neck and spine). Subjects were categorized as
fracture free or having had a previous fracture as described previ-
ously,30 with fractures sustained at any skeletal site up to 2003
included in the analysis but those caused by high-impact trauma
excluded. Informed consent was obtained from each individual,
and the study was approved by the local ethics committee.
Genotyping
Genomic DNAwas extracted and puriﬁed from EDTAwhole blood
obtained from each subject.31 Genotyping in the discovery cohort
was performed with the Illumina GoldenGate assay on an Illu-
mina BeadStation 500 GX and utilized bead-array hybridization32
with genomic whole-genome ampliﬁed (Repli-g) DNA. The geno-
type call rate with this technique was 99.8%, with an error rate
of < 0.1%.
Genotyping in the replication cohort was performed with
matrix-assisted laser desorption and ionization time of ﬂight
(MALDI-ToF) mass spectrometry as described previously.33 ForThe Amthis technique, the genotype call rate was 97.7% and the estimated
error rate was < 0.1%.
SNP Selection
Seventeen single-nucleotide polymorphisms (SNPs) were selected
in the region of theARHGEF3 gene for genotyping in the discovery
cohort. Tagging SNPs (tSNPs) were initially selected across the re-
gion with the Perlegen Genome Browser Version 1,34 which iden-
tiﬁes tSNPs as being in linkage disequilibrium (LD) of r2R 0.8 with
all other SNPs in the LD bin. We attempted to tag all 13 LD bins
that were identiﬁed by Perlegen within the gene and the 50 Kb
region 50 of the gene and contained two or more SNPs. Because
of assay design issues, we were able to tag nine of the 13 LD
bins. The remaining SNPs genotyped were selected from the Perle-
gen Genome Browser as single SNPs not belonging to any LD bin,
or they were selected from dbSNP.
Statistical Analysis
All SNPs were in Hardy-Weinberg equilibrium (c2 test, p < 0.05).
Analysis of the data from the discovery cohort was performed with
the family-based association tests (FBAT) software to test for associ-
ation within sib pairs.35 The empirical variance estimator was used
to allow for prior linkage to the region. The results were adjusted
formultiple testing bypermutingof thephenotypeswithin sibships
with genotypes held constant. The minimum p values were re-
corded for 10,000 random reassignments of the data (with an auto-
mated scriptwritten inPerl),withanadjustedpvalue%0.05consid-
ered signiﬁcant. For individual BMD scores, with multiple SNPs
adjusted for, this corresponds to an unadjusted p value of about
0.0037. For adjustment for testing BMD scores at three sites, the cor-
responding unadjusted p value was 0.002. To examine the effect of
reducing the number of the correlated traits, we carried out princi-
pal-component analysis. The effect of menopausal status on BMD
in the discovery cohortwas analyzedwithmultiple linear regression
implemented in STATISTICA version 8.0 (StatSoft, Tulsa, OK, USA).
Haplotype analysis used QPDTPHASE, part of the UNPHASED
suite,36 which is a program for association analysis of multilocus
haplotypes from unphased genotype data. Throughout, two-tailed
p values are reported,with adjusted p% 0.05 considered signiﬁcant.
LD between the different SNPs was evaluated with the software
JLIN37 and graphical overview of linkage disequilibrium (GOLD).38
Statistical analysis of the data from the replication cohort was
performed with one-way ANOVA for differences between geno-
type groups. BMD data were adjusted for age and weight by anal-
ysis of covariance (ANCOVA). Genotype effects on the prevalent
fracture rate were examined with a Chi-square test.
Results
Discovery Cohort
The mean age of the discovery cohort was 54.25 12.7 yr;
other demographic and morphometric characteristics of
the populations are detailed in Table 1. The discovery
cohort recorded a lower mean BMD than the replication
cohort at each site studied despite a younger mean age,
which was expected because of the high proportion of os-
teoporotic individuals in this population. For the total-hip
and femoral-neck sites, menopausal status was not a signif-
icant predictor of BMD. At the spine, menopausal status
was found to account for < 1% of the variance in BMD.erican Journal of Human Genetics 82, 1262–1269, June 2008 1263
The location of the 17 SNPs studied relative to the splice
variants of ARHGEF3 are displayed in Figure 1. With FBAT,
signiﬁcant associations were seen between the SNPs
rs4681928, rs1344142, rs1110866, rs7646054, and
rs3772219 and various measures of BMD Z score (p ¼
0.0007–0.041). The chromosomal position and allele dis-
tribution of these ﬁve SNPs are detailed in Table 2. The
strongest associations were observed with rs7646054,
which was associated with BMD Z score at the total hip
(p ¼ 0.006), femoral neck (p ¼ 0.0007), and spine (p ¼
0.006). Among the other SNPs, rs4681928was signiﬁcantly
associated with BMD Z score of the femoral neck (p¼ 0.01)
and spine (p ¼ 0.03), rs1344142 with spine (p ¼ 0.04),
rs1110866 with femoral neck (p ¼ 0.02), and rs3772219
with spine (p ¼ 0.03). Signiﬁcant association with
rs7646054 was maintained after correction for testing mul-
tiple anatomical sites (p ¼ 0.015). The signiﬁcant associa-
tion between rs7646054 and femoral-neck BMD Z score
persisted after adjustment of the data for testing multiple
SNPs (p ¼ 0.007), as did the association corrected further
for testing multiple anatomical sites (p ¼ 0.024).
Table 1. Demographics and Bone Density of the Discovery
and Replication Populations
Variable Discovery Replication
Age (yr) 54.25 12.7 (769) 62.5 5 5.9 (780)
Weight (kg) 62.75 11.27 (699) 69.1 5 12.6 (778)
Prevalent
fractures (%)
- 34 (780)
Total-hip DXA
BMD (mg/cm2)
8015 136 (760) 8695 128 (775)
Total-hip
BMD Z Score
0.4205 0.992 (760) 0.4895 0.994 (775)
Femoral-neck
DXA BMD (mg/cm2)
7005 133 (749) 7475 119 (775)
Femoral-neck
BMD Z score
0.3555 1.050 (749) 0.2765 1.019 (775)
Spine L1-L4
DXA BMD (mg/cm2)
8555 158 (767) 9555 155 (779)
Spine BMD Z score 0.6695 1.252 (767) 0.7455 1.384 (779)
Results are given as mean5 SD (number of measurements).1264 The American Journal of Human Genetics 82, 1262–1269, JunWe also applied principal-component analysis to the
BMD trait group. The ﬁrst two principal components
explained 94.5% of the trait variance. However, with the
eigenvalue > 1 criterion used, only the ﬁrst component,
which explained 77.3% of the variance in BMD, should
be retained. This component showed maximal association
with rs7646054 (p ¼ 0.002).
The more common G allele at rs7646054 is associated
with a lower BMD Z score at each site studied (Table 3), in-
dicating that this allele has a negative effect on BMD. Note
that the mean BMD Z scores reported by QPDTPHASE are
loosely interpreted as the expected trait value for an indi-
vidual carrying that particular allele and are not interpret-
able as additive effects on the mean.
Pair-wise linkage disequilibrium D’ and r2 values for the
ﬁve SNPs are shown in Figure 2. A haplotype analysis was
undertaken on the femoral-neck and spine BMD Z score
data with UNPHASED to determine whether any haplo-
types were more strongly associated with either phenotype
than individual SNPs. Each haplotype analysis incorpo-
rated only the three SNPs that weremost signiﬁcantly asso-
ciated with the phenotype in the FBAT analysis. For femo-
ral-neck BMD Z score, the SNPs included in the haplotype
analysis were rs4681928, rs1110866, and rs7646054,
whereas the SNPs rs4681928, rs7646054, and rs3772219
were included in the spineBMDZ score analysis. Signiﬁcant
associationswere observedwith both phenotypes (Table 4),
including a stronger overall association with spine BMD Z
score than in the individual SNP analysis, suggesting inde-
pendent effects of the SNPs on BMD. In the femoral-neck
BMD haplotype analysis, the signiﬁcance of the overall as-
sociation did not surpass that of the individual SNP analy-
sis. However, a very strong association was observed be-
tween the AAA haplotype and femoral-neck BMD Z score
in the individual haplotype analysis (p < 0.0004).
Replication Study
Because rs7646054 was the strongest predictor of spine and
hipbonedensity, itwas taken forwardtothereplicationstudy
todeterminewhether the effectwouldbedetectable inapop-
ulation-based cohort of postmenopausal women. SigniﬁcantFigure 1. Diagram Showing the Localization of the 17 SNPs Analyzed in ARHGEF3 and the Splice Variants of the Gene According to
the UCSC Genome Browser, March 2006 Assembly
The SNPs highlighted in red are those that are significantly associated with BMD parameters in the discovery cohort prior to adjustment
for multiple testing.e 2008
Table 2. Position and Allele Distribution of the Five SNPs in ARHGEF3 that Demonstrated Significant Associations with BMD
SNP Chromosome Positiona Location and Functiona
Genotype Distribution in the Discovery
Cohort (%)
rs4681928 56901206 50 region AA (63.6), AG (33.5), GG (2.9)
rs1344142 56832473 50 region GG (26.4), AG (52.6), AA (21)
rs1110866 56801364 Intron 1 AA (41.2), AC (47.2), CC (11.6)
rs7646054 56784668 Intron 1 GG (29.1) (33.2)b, AG (52.1) (47.4)b,
AA (18.8) (19.4)b
rs3772219 56746291 Exon 8, Change of amino acid
335 (Leu to Val)
TT (45.6), TG (42.5), GG (11.9)
a From GenBank reference sequence NM_019555, Genome Build 36.2. b Allele distribution in the replication cohort.associations were observed between rs7646054 and spine
and total-hip BMD including the femoral-neck area, all of
which persisted after adjustment of the BMDdata for the co-
variates age andweight (Table 5). Consistent with the results
for thediscoverycohort, subjectshomozygous for theGallele
compared to individuals homozygous for the A allele had
lower BMD at the total-hip, femoral-neck, and spine sites
(3.7%,3.3%, and3.5%, respectively). Compared to het-
erozygous individualswith theAG genotype,GG individuals
again had lower BMD at the three sites (1.8%,2.4%, and
3.7%, respectively). No signiﬁcant associations between
genotype and the covariates age or weight were found.
An allelic association test of the replication cohort with
BMD Z score as the phenotype was then carried out with
QTPHASE to conﬁrm replication with the same type of as-
sociation test and the same phenotype as that used for the
discovery cohort. Signiﬁcant associations were observed
between rs7646054 and total-hip BMD Z score (p ¼
0.007), femoral-neck BMD Z score (p ¼ 0.02), and spine
BMD Z score (p ¼ 0.02).
In the replication cohort, 265 subjects had suffered
a fracture prior to 2004, giving a prevalent fracture rate
of 34%. rs7646054 was found to be signiﬁcantly associated
with fracture rate, withGG individuals having an increased
fracture rate (Table 5).
Discussion
The data presented in this study provide evidence that var-
iation within the ARHGEF3 gene affects BMD in women
Table 3. Genetic Data for rs7646054 Relevant to BMD Z Score
in the Discovery Cohort
BMD Z Score
Phenotype
Mean BMD Z Score
p ValueG Allele A Allele
Total hip 0.4375 1.235
(837)
0.3995 1.222 (683) 0.013
Femoral
neck
0.3835 1.325
(825)
0.3225 1.264 (673) 0.001
Spine 0.6865 1.619
(842)
0.6505 1.538 (692) 0.008
Results are given as mean 5 SD (number of alleles contributing to the
mean), derived from QPDTPHASE.The Amaged 40 to 70 in the peri- and early postmenopausal phase
of life, at the time that fracture risk is rising. We found
strong evidence for an inﬂuence of individual SNPs and
haplotypes on spine and femoral-neck BMD Z score.
rs7646054 within intron 1 of the ARHGEF3 gene (NCBI
accession number NM_019555) was the best predictor of
bone density, and the results were replicated in a second
cohort including a statistically signiﬁcant association
with fracture rate. In general, fracture risk rises by about
two times for a reduction in hip BMD of one standard
deviation (SD) (15% of the mean).39 We saw decreases in
BMD of about 3% that equate to an increase in fracture
risk for the ‘‘disease’’ genotype of about 20%, in keeping
with the observed fracture rate in the replication cohort.
Given that rs7646054 is located within an intron, it is
unlikely that polymorphism at this site would have a direct
effect on the ARHGEF3 gene product. Analysis of the SNPs
in strong LD with rs7646054 provided no further evidence
as to themechanism by which the ARHGEF3 protein could
be affected by the observed polymorphism. However,
rs7646054 is located within the 50 UTR of a recently
described splice variant of the ARHGEF3 gene (NCBI acces-
sion number AB209661). It is therefore possible that poly-
morphism at this site has an effect on the mRNA folding of
this splice variant.
Using the genetic power calculator developed by Purcell
and colleagues,40 with QTL variance set as 0.05, QTL and
marker frequency of 0.5 and 0.55, respectively, D’ ¼ 0.9,
and sib correlation of 0.4, the power of the discovery co-
hort is 0.91 at a type I error rate of 0.05. If the QTL variance
is only 0.03, then the power is 0.72. Similarly for the repli-
cation cohort, if the QTL variance is set as 0.05, then the
power for this study is 0.99, whereas for a QTL variance
of 0.03 the power is 0.98.
ARHGEF3was ﬁrst described in 200222 and is a rho-family
guanine-nucleotide exchange factor containing two do-
mains: a Dbl homology domain, which is responsible for
catalytic activity, andapleckstrinhomologydomain,which
is thought to target the GEFs to the plasma membrane and
provide a site for regulation by phospholipids.41 When ex-
pressed in ﬁbroblasts, ARHGEF3 has been shown to cause
theassemblyofmore robust stressﬁbers and focal adhesions
than in ﬁbroblasts not expressing the protein through
speciﬁc activation of the RHOA and RHOB GTPases.22erican Journal of Human Genetics 82, 1262–1269, June 2008 1265
A role of the RhoGEFs such as ARHGEF3 is to activate
RhoGTPases, key actin-dynamics regulators that cycle be-
tween an inactive GDP-bound and an active GTP-bound
state. RhoGEFs achieve this by catalyzing the exchange
of GDP for GTP through stabilization of the nucleotide-
free state.42 GTP then spontaneously binds and renders
the protein active. RHOA has been implicated in osteoblast
differentiation. McBeath et al.43 demonstrated that RHOA
expression committed human mesenchymal stem cells
(hMSCs) to an osteoblastic fate, whereas expression of
dominant-negative RHOA caused adipogenesis. These ef-
fects even overrode the presence of differentiation factors
in the media and are thought to occur through effects on
cytoskeletal tension.43 Meyers et al.24 found that overex-
pression of RHOA restored actin cytoskeletal arrangement,
enhanced the expression of osteoblastic genes, and sup-
pressed the expression of adipocytic genes in hMSCs cul-
tured in modeled microgravity (MMG). Interestingly, it
was found that the quantity of activated RHOA dropped
Figure 2. Pairwise Linkage Disequilib-
rium Plot for the Five Associated SNPs
in the ARHGEF3 Gene in the Discovery
Population
Different colors represent the strength of
LD according to the scale shown on the
right.
Table 4. BMD Z Scores for ARHGEF3 3-SNP Haplotypes
BMD Z Score
Phenotype
Haplotype (rs4681928, rs1110866, rs7646054)
AAA Allele GAA Allele AAG Allele GAG Allele ACG Allele GCG Allele p Value
Femoral neck 0.3415 1.188
(588)c
0.2055 1.072
(81)
0.4085 1.129
(239)
0.3595 0.781
(65)
0.3765 1.162
(374)
0.3585 0.974
(144)a
0.003
Haplotype (rs4681928, rs7646054, rs3772219)
AAT Allele AGT Allele GGT Allele AAG Allele AGG Allele GGG Allele p Value
Spine 0.5735 1.299
(375)a
0.6775 1.378
(450)a
0.7255 1.161
(151)b
0.7205 1.187
(228)a
0.6655 1.171
(177)
0.7225 0.864
(61)
0.002
Results are given as mean 5 SD (number of alleles contributing to the mean), derived from QPDTPHASE. a p < 0.05, b p < 0.01, and c p < 0.0004 for
individual haplotypes compared to all others.
by 88% 5 2% in hMSCs cultured in
MMG, whereas the total expression
of RHOA did not change signiﬁ-
cantly,24 indicating that the RhoGEFs
responsible for activating RHOA
could have had a role in the effect.
Osteoclasts are highly motile cells
that rely on rapid changes to their
cytoskeleton to achieve the move-
ment and attachment that is re-
quired for bone resorption.44–47 Chel-
laiah et al.23 identiﬁed RHOA as
playing a major role in this process.
By transducing active and inactive
RHOA into avian osteoclasts, they demonstrated that the
protein is essential for podosome assembly, stress-ﬁber
formation, osteoclast motility, and bone resorption.23 In
addition, farnesyl pyrophosphate synthase, the speciﬁc
target of nitrogen-containing bisphosphonates widely
used in the treatment of osteoporosis, is essential for the
prenylation and therefore activity of RhoGTPases includ-
ing RHOA.48 Bisphosphonates cause loss of osteoclast
activity and induction of apoptosis, possibly through the
inactivation of RhoGTPases.49 The known interaction of
ARHGEF3 with RHOA and potential role of ARHGEF3 in
that signal-transduction pathway strongly suggest that
variation in ARHGEF3 is associated with regulated function
in bone cells—probably osteoclasts. Osteoclasts treated
with dexamethasone showed prolonged longevity with
decreased spreading, actin ring formation, and bone-
degrading activity as the result of altered cytoskeletal orga-
nization.50 This may be mediated by arrested macrophage
colony-stimulating factor (M-CSF)-stimulated activation of1266 The American Journal of Human Genetics 82, 1262–1269, June 2008
Table 5. Osteodensitometry Parameters and Fracture Rate in Relation to the Genotype Distribution of rs7646054 in the
Replication Cohort
Phenotype AA Genotype AG Genotype GG genotype p Value
Total-hip DXA BMD (mg/cm2) 8895 128a (150) 8725 128a (354) 8575 122b (252) 0.013
Femoral-neck DXA BMD (mg/cm2) 7595 115a (150) 7535 120a (354) 7355 117b (252) 0.038
Spine DXA BMD (mg/cm2) 9675 172a (150) 9695 148a (356) 9345 152b (253) 0.007
Prevalent fracture (%) 36.4 (151) 29.1 (358) 39.1 (253) 0.026
Results are given as mean5 SD (number of measurements). The BMD data are adjusted for age and weight. a is significantly different from b in posthoc
analysis (p < 0.05).certain RhoGEFs and RhoGTPases including RHOA.50 Fi-
nally, RHOB has a role in cartilage biology, having been
linked to osteoarthritis, in which a chondrocyte disorder
plays a major role.25,26
In conclusion, we have shown that genetic variation
within the ARHGEF3 gene is associated with variation in
BMD in Caucasian women. There is a signiﬁcant amount
of evidence to suggest that the two RhoGTPases that are
speciﬁcally activated by ARHGEF3, RHOA, and RHOB
have a role in bone cell biology. Furthermore, there is evi-
dence of a skeletal phenotype for mutations in an associ-
ated gene, FGD1, which regulates the RhoGTPase CDC42
(MIM 116952).
Further research needs to be conducted to determine the
primary ARHGEF3 splice variant in bone cells and the
mechanism by which the identiﬁed polymorphism,
rs7646054 (or a SNP in strong LD with it), affects the
ARHGEF3 protein. However, the data presented here raise
the possibility that variation in the RhoGTPase pathway
of cell regulation may represent new targets for pharma-
ceutical development in the same way that the discovery
of the importance of the Wnt signaling pathway involving
LRP5 in skeletal function has led to new understanding of
and potential new therapy for osteoporosis.51
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